Aptamer Group, PinotBio collaborate to develop Optimer-drug conjugates
Aptamer Group, the developer of Optimer Therapeutics, and PinotBio (Gyeonggi-do, Korea), a clinical-stage oncology-focused biotechnology company, have entered into a strategic collaboration agreement. The agreement is to develop Optimer-drug conjugates for targeted drug delivery combining Aptamer Group’s Optimer technology with PinotBio’s technology using the chemotherapeutic FL-118 compound with specific linker.
